SCHEMBL4298025

SCHEMBL4298025

CCOc1ccc(C(=O)NC(C)(C)CN)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.59
NPC1 O15118 4/20 0.55
RAB9A P51151 3/20 0.55
PARP10 Q53GL7 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
TP53 P04637 1/20 0.54
EPHX2 P34913 1/20 0.53
NR1H4 Q96RI1 1/20 0.53
NPSR1 Q6W5P4 2/20 0.52
HPGD P15428 1/20 0.52
ALDH1A1 P00352 2/20 0.51
KDM4E B2RXH2 1/20 0.51
CYP1A2 P05177 1/20 0.51
TAS1R3 Q7RTX0 1/20 0.51
TAS1R1 Q7RTX1 1/20 0.51
POLB P06746 1/20 0.51
AOC3 Q16853 2/20 0.50
LMNA P02545 2/20 0.50
MAOB P27338 1/20 0.50
MAPT P10636 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21116106 0.88 PLK1 (0.63) PLK1NPC1RAB9APARP10SMN1; SMN2
SCHEMBL18382537 0.84 PLK1 (0.67) PLK1NPC1RAB9APARP10SMN1; SMN2
SCHEMBL13366255 0.82 PLK1 (0.52) PLK1NPC1RAB9APARP10SMN1; SMN2
SCHEMBL13611517 0.79 PLK1 (0.52) PLK1NPC1RAB9ASMN1; SMN2TP53
SCHEMBL2636457 0.79 PLK1 (0.73) PLK1NPC1RAB9APARP10SMN1; SMN2
SCHEMBL4563637 0.78 PLK1 (0.51) PLK1NPC1RAB9APARP10SMN1; SMN2
SCHEMBL27745010 0.78 POLB (0.47) NPC1RAB9APOLBAOC3LMNA
SCHEMBL18659081 0.77 PLK1 (0.56) PLK1NPC1RAB9APARP10SMN1; SMN2
SCHEMBL24110662 0.76 PLK1 (0.65) PLK1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL28590876 0.76 PLK1 (0.69) PLK1NPC1RAB9APARP10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed
WO-2008011131-A2 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286791-A1 Amide Compounds DLAT, DGAT2, DGAT1 PLK1 4082/4885NPC1 214/4885RAB9A 2100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.